Patents by Inventor Benjamin Maynor
Benjamin Maynor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230346799Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: July 12, 2023Publication date: November 2, 2023Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 11744835Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: GrantFiled: July 30, 2021Date of Patent: September 5, 2023Assignee: Liquidia Technologies, Inc.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 11744836Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: GrantFiled: July 30, 2021Date of Patent: September 5, 2023Assignee: Liquidia Technologies, Inc.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 11712442Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: GrantFiled: November 25, 2020Date of Patent: August 1, 2023Assignee: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 11660304Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: GrantFiled: April 13, 2022Date of Patent: May 30, 2023Assignee: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20220257608Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: April 13, 2022Publication date: August 18, 2022Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20220080049Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise ocular implants having a desired extended drug release profile suitable for treating elevated intraocular pressure.Type: ApplicationFiled: March 25, 2021Publication date: March 17, 2022Inventors: Andres Garcia, Benjamin Maynor, Janet Tully, Benjamin Robinson Yerxa, Tomas Navratil, Sanjib Kumar Das
-
Publication number: 20210353640Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: July 30, 2021Publication date: November 18, 2021Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20210353641Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: July 30, 2021Publication date: November 18, 2021Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20210077504Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: November 25, 2020Publication date: March 18, 2021Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 10898494Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: GrantFiled: May 5, 2017Date of Patent: January 26, 2021Assignee: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 10717209Abstract: A laminate nanomold includes a layer of perfluoropolyether defining a cavity that has a predetermined shape and a support layer coupled with the layer of perfluoropolyether. The laminate can also include a tie-layer coupling the layer of perfluoropolyether with the support layer. The tie-layer can also include a photocurable component and a thermal curable component. The cavity can have a broadest dimension of less than 500 nanometers.Type: GrantFiled: May 25, 2017Date of Patent: July 21, 2020Assignee: LIQUIDIA TECHNOLOGIES, INC.Inventors: Jason P. Rolland, Benjamin Maynor, Robert Lyon Henn
-
Publication number: 20190209538Abstract: A composition to induce analgesia includes a plurality of particles, each particle of the plurality having 40-60 wt % amino amide anesthetic or a pharmaceutically acceptable salt, hydrate, or solvate thereof and 60-40 wt % PLGA polymer including 48:52 to 52:48 molar ratio D,L lactide:glycolide and an inherent viscosity of about 0.16 to 0.24 dL/g at 0.1% w/v in chloroform at 25° C. Each particle includes a non-spherical shape less than 100 ???? in a broadest dimension, and having a volume of about 13,500 cubic micrometers. The amino amide anesthetic is crystalline and includes 50-70% crystalline form I and 30-50% crystalline form II.Type: ApplicationFiled: May 5, 2017Publication date: July 11, 2019Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: John Robert Savage, Jacob J. Sprague, Ashley Galloway, Geoffrey Hird, Marquita Nicole Lilly, Akihisa Nonoyama, Edward Graham Randles, Benjamin Maynor
-
Publication number: 20190151332Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: May 5, 2017Publication date: May 23, 2019Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20170259461Abstract: A laminate nanomold includes a layer of perfluoropolyether defining a cavity that has a predetermined shape and a support layer coupled with the layer of perfluoropolyether. The laminate can also include a tie-layer coupling the layer of perfluoropolyether with the support layer. The tie-layer can also include a photocurable component and a thermal curable component. The cavity can have a broadest dimension of less than 500 nanometers.Type: ApplicationFiled: May 25, 2017Publication date: September 14, 2017Applicant: Liquidia Technologies, Inc.Inventors: Jason P. Rolland, Benjamin Maynor, Robert Lyon Henn
-
Patent number: 9662809Abstract: A laminate nanomold includes a layer of perfluoropolyether defining a cavity that has a predetermined shape and a support layer coupled with the layer of perfluoropolyether. The laminate can also include a tie-layer coupling the layer of perfluoropolyether with the support layer. The tie-layer can also include a photocurable component and a thermal curable component. The cavity can have a broadest dimension of less than 500 nanometers.Type: GrantFiled: April 26, 2016Date of Patent: May 30, 2017Assignee: Liquidia Technologies, Inc.Inventors: Jason P. Rolland, Benjamin Maynor, Robert Lyon Henn
-
Publication number: 20170144336Abstract: A system including a mold having a fluoropolymer wherein the mold defines a plurality of cavities having a predetermined shape and a cross-sectional dimension less than about 100 micrometers; a roller; a surface in cooperation with the roller to form a nip point configured to receive the mold, wherein the nip point is further configured to receive a substantially liquid composition and accelerate entry of the substantially liquid composition into the cavity.Type: ApplicationFiled: January 10, 2017Publication date: May 25, 2017Applicant: Liquidia Technologies, Inc.Inventors: Robert Henn, Alex Ermoshkin, Kyle Henn, Benjamin Maynor, Jason Rolland, Robert Praino
-
Patent number: 9545737Abstract: A system including a mold having a fluoropolymer wherein the mold defines a plurality of cavities having a predetermined shape and a cross-sectional dimension less than about 100 micrometers; a roller; a surface in cooperation with the roller to form a nip point configured to receive the mold, wherein the nip point is further configured to receive a substantially liquid composition and accelerate entry of the substantially liquid composition into the cavity.Type: GrantFiled: July 25, 2013Date of Patent: January 17, 2017Assignee: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Henn, Alex Ermoshkin, Kyle Henn, Benjamin Maynor, Jason Rolland, Robert Praino
-
Publication number: 20160296627Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise ocular implants having a desired extended drug release profile suitable for treating elevated intraocular pressure.Type: ApplicationFiled: December 5, 2014Publication date: October 13, 2016Applicant: Envisia Therapeutics Inc.Inventors: Andres Garcia, Benjamin Maynor, Janet Tully, Benjamin Robinson Yerxa, Tomas Navratil, Sanjib Kumar Das
-
Publication number: 20160236379Abstract: A laminate nanomold includes a layer of perfluoropolyether defining a cavity that has a predetermined shape and a support layer coupled with the layer of perfluoropolyether. The laminate can also include a tie-layer coupling the layer of perfluoropolyether with the support layer. The tie-layer can also include a photocurable component and a thermal curable component. The cavity can have a broadest dimension of less than 500 nanometers.Type: ApplicationFiled: April 26, 2016Publication date: August 18, 2016Applicant: Liquidia Technologies, Inc.Inventors: Jason P. Rolland, Benjamin Maynor, Robert Lyon Henn